Related to Pfizer to Study Liver Cancer in Korean Patients with Samsung Medical Center

• Two Phase III Studies Confirm Benefits of Pfizer’s Tofacitinib Against Active RA
  
• FDA Approves Type 2 Diabetes Drug from Boehringer Ingelheim and Lilly
  
• FDA Rubber-Stamps Merck’s Victrelis as Combination Therapy for Chronic Hepatitis C
  
• Amylin Takes Lilly to Court over Diabetes Drug Development Deal with Boehringer Ingelheim
  
• Phase III Trial Finds Pfizer’s Axitinib Better than Sorafenib at Boosting PFS in Renal Cell Cancer
  
• FDA Expands Sutent Label to Include Pancreatic Neuroendocrine Tumors
  
• Lilly Sets Up New Firm to Expand Sepsis Drug Xigris
  
• Amylin Obtains Temporary Restraining Order Against Eli Lilly
  
• Merck & Co. Teams with Roche to Develop Companion Diagnostics for Cancer Therapy
  
• Intercell and Merck Terminate Phase II/III S. aureus Preventive Vaccine Trial
  
• Court Vacates Temporary Restraining Order Against Lilly in Case Filed by Amylin
  
• Merck & Co. Teams with Hanwha to Develop Biosimilar Enbrel
  
• EC Approves Lilly, Amylin, and Alkermes’ Once-Weekly Type 2 Diabetes Drug Bydureon
  
• BioMarin Pays $48.5M for Pfizer’s Biologics Production Plant in Ireland
  
• Promising Data for Type 1 and 2 Diabetes Candidates Presented at ADA Meeting
  
• Lilly to Invest Millions into Multispecific Therapeutics R&D
  
• Japan Approves Merck & Co.’s Gardasil, Zolinza, and Cubicin
  
• Aslan Pharmaceuticals Licenses Array’s Phase II-Stage Solid Tumor Candidate
  
• Merck & Co. and Roche Go Global with Marketing for Victrelis in HCV
  
• Pfizer to Pay $49.8M for Icagen to Pad Focus on Pain Therapy